Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Increase in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 39,109 shares, an increase of 4,114.3% from the November 30th total of 928 shares. Approximately 4.0% of the company’s shares are sold short. Based on an average daily volume of 189,317 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 189,317 shares, the short-interest ratio is currently 0.2 days. Approximately 4.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SNSE. HC Wainwright lowered Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 16,295 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $11.50, for a total transaction of $187,392.50. Following the completion of the sale, the insider directly owned 161,359 shares in the company, valued at $1,855,628.50. This represents a 9.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have sold 27,907 shares of company stock valued at $287,280. 23.20% of the stock is owned by company insiders.

Sensei Biotherapeutics Stock Performance

Shares of SNSE stock traded up $0.06 during trading hours on Wednesday, reaching $9.27. The company had a trading volume of 4,884 shares, compared to its average volume of 61,420. The stock’s fifty day simple moving average is $9.44 and its 200 day simple moving average is $8.79. The company has a market capitalization of $11.67 million, a P/E ratio of -0.48 and a beta of 0.32. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, November 14th. The company reported ($3.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.11) by $0.49. As a group, equities analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.